Literature DB >> 27775243

Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases.

Petra Břehová1, Markéta Šmídková1, Jan Skácel1, Martin Dračínský1, Helena Mertlíková-Kaiserová1, Monica P Soto Velasquez2, Val J Watts2, Zlatko Janeba1.   

Abstract

Bordetella pertussis adenylate cyclase toxin (ACT) and Bacillus anthracis edema factor (EF) are key virulence factors with adenylate cyclase (AC) activity that substantially contribute to the pathogenesis of whooping cough and anthrax, respectively. There is an urgent need to develop potent and selective inhibitors of bacterial ACs with prospects for the development of potential antibacterial therapeutics and to study their molecular interactions with the target enzymes. Novel fluorescent 5-chloroanthraniloyl-substituted acyclic nucleoside phosphonates (Cl-ANT-ANPs) were designed and synthesized in the form of their diphosphates (Cl-ANT-ANPpp) as competitive ACT and EF inhibitors with sub-micromolar potency (IC50 values: 11-622 nm). Fluorescence experiments indicated that Cl-ANT-ANPpp analogues bind to the ACT active site, and docking studies suggested that the Cl-ANT group interacts with Phe306 and Leu60. Interestingly, the increase in direct fluorescence with Cl-ANT-ANPpp having an ester linker was strictly calmodulin (CaM)-dependent, whereas Cl-ANT-ANPpp analogues with an amide linker, upon binding to ACT, increased the fluorescence even in the absence of CaM. Such a dependence of binding on structural modification could be exploited in the future design of potent inhibitors of bacterial ACs. Furthermore, one Cl-ANT-ANP in the form of a bisamidate prodrug was able to inhibit B. pertussis ACT activity in macrophage cells with IC50 =12 μm.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  adenylate cyclase; anthrax; antibacterial agents; fluorescence; whooping cough

Mesh:

Substances:

Year:  2016        PMID: 27775243      PMCID: PMC5198786          DOI: 10.1002/cmdc.201600439

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  55 in total

1.  Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.

Authors:  Dana Hocková; Dianne T Keough; Zlatko Janeba; Tzu-Hsuan Wang; John de Jersey; Luke W Guddat
Journal:  J Med Chem       Date:  2012-06-22       Impact factor: 7.446

Review 2.  Duration of immunity against pertussis after natural infection or vaccination.

Authors:  Aaron M Wendelboe; Annelies Van Rie; Stefania Salmaso; Janet A Englund
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

Review 3.  Bordatella pertussis adenylate cyclase: a toxin with multiple talents.

Authors:  D Ladant; A Ullmann
Journal:  Trends Microbiol       Date:  1999-04       Impact factor: 17.079

4.  Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

Authors:  Gabriel Birkus; Ruth Wang; Xiaohong Liu; Nilima Kutty; Holly MacArthur; Tomas Cihlar; Craig Gibbs; Swami Swaminathan; William Lee; Martin McDermott
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli.

Authors:  Z Zídek; D Franková; A Holý
Journal:  Int J Immunopharmacol       Date:  2000-12

6.  Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.

Authors:  Brett D Allison; Victor K Phuong; Laura C McAtee; Mark Rosen; Magda Morton; Clodagh Prendergast; Terry Barrett; Guy Lagaud; Jamie Freedman; Lina Li; Xiaodong Wu; Hariharan Venkatesan; Marna Pippel; Craig Woods; Michèle C Rizzolio; Michael Hack; Kenway Hoey; Xiaohu Deng; Christopher King; Nigel P Shankley; Michael H Rabinowitz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

7.  First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.

Authors:  Wai Soon Eng; Dana Hocková; Petr Špaček; Zlatko Janeba; Nicholas P West; Kyra Woods; Lieve M J Naesens; Dianne T Keough; Luke W Guddat
Journal:  J Med Chem       Date:  2015-05-13       Impact factor: 7.446

8.  GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma.

Authors:  Hans Reiser; Jianying Wang; Lee Chong; William J Watkins; Adrian S Ray; Riri Shibata; Gabriel Birkus; Tomas Cihlar; Sylvia Wu; Bei Li; Xiaohong Liu; Ilana N Henne; Grushenka H I Wolfgang; Manoj Desai; Gerald R Rhodes; Arnold Fridland; William A Lee; William Plunkett; David Vail; Douglas H Thamm; Robert Jeraj; Daniel B Tumas
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.

Authors:  Dianne T Keough; Dana Hocková; Dominik Rejman; Petr Spaček; Silvie Vrbková; Marcela Krečmerová; Wai Soon Eng; Harmen Jans; Nicholas P West; Lieve M J Naesens; John de Jersey; Luke W Guddat
Journal:  J Med Chem       Date:  2013-08-27       Impact factor: 7.446

10.  2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors.

Authors:  Andreas Gille; Roland Seifert
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

View more
  5 in total

Review 1.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

2.  Halogen-Dance-Based Synthesis of Phosphonomethoxyethyl (PME) Substituted 2-Aminothiazoles as Potent Inhibitors of Bacterial Adenylate Cyclases.

Authors:  Michal Česnek; Michal Šafránek; Martin Dračínský; Eva Tloušťová; Helena Mertlíková-Kaiserová; Michael P Hayes; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2021-10-22       Impact factor: 3.466

Review 3.  Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.

Authors:  Marcela Krečmerová; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  Front Chem       Date:  2022-05-20       Impact factor: 5.545

4.  Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.

Authors:  Petra Břehová; Ema Chaloupecká; Michal Česnek; Jan Skácel; Martin Dračínský; Eva Tloušťová; Helena Mertlíková-Kaiserová; Monica P Soto-Velasquez; Val J Watts; Zlatko Janeba
Journal:  Eur J Med Chem       Date:  2021-05-28       Impact factor: 7.088

5.  Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.

Authors:  Elisa Pileggi; Michaela Serpi; Graciela Andrei; Dominique Schols; Robert Snoeck; Fabrizio Pertusati
Journal:  Bioorg Med Chem       Date:  2018-05-23       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.